GT Biopharma DB:OXIA Stok Raporu Şirket Finansalları + 1 Analist
GT Biopharma, Inc.
DB:OXIA Stok Raporu
OXIA Stoklara Genel Bakış A clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform.
Ödüller Risk Analizi + 1 daha fazla risk
Tüm Risk Kontrollerini Gör GT Biopharma, Inc. Rakipler Fiyat Geçmişi ve Performans
için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti GT Biopharma Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$4.77 52 Haftanın En Yüksek Seviyesi US$10.74 52 Haftanın En Düşük Seviyesi US$4.77 Beta 0.57 11 Aylık Değişim 0% 3 Aylık Değişim -9.66% 1 Yıllık Değişim -48.71% 33 Yıllık Değişim -98.53% 5 Yıllık Değişim n/a Halka arzdan bu yana değişim -96.48%
Son Haberler & Güncellemeler
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia Jun 27
GT Biopharma, Inc. Announces CFO Changes Jun 10 GT Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $3.219 million. May 22
GT Biopharma, Inc., Annual General Meeting, Jun 25, 2024 May 01
GT Biopharma Announces 1 for 30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Feb 02
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia Dec 04 Daha fazla güncelleme görün
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia Jun 27
GT Biopharma, Inc. Announces CFO Changes Jun 10 GT Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $3.219 million. May 22
GT Biopharma, Inc., Annual General Meeting, Jun 25, 2024 May 01
GT Biopharma Announces 1 for 30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Feb 02
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia Dec 04 GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting Nov 07
Nasdaq Listing Qualifications Department Determines the GT Biopharma's Eligibility for an Additional 180 Calendar Day Period, or Until February 20, 2024, to Regain Compliance Aug 23
New major risk - Revenue and earnings growth Aug 08
High number of new and inexperienced directors Jul 26 Hissedar Getirileri OXIA DE Biotechs DE Pazar 7D 0% -2.2% 1.1% 1Y -48.7% -17.1% 13.5%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: OXIA geçen yıl % -17.1 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: OXIA geçen yıl % 13.5 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is OXIA's price volatile compared to industry and market? OXIA volatility OXIA Average Weekly Movement n/a Biotechs Industry Average Movement 5.8% Market Average Movement 4.7% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: OXIA hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: OXIA 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri .
Şirket Hakkında Daha fazla göster GT Biopharma, Inc. Temel Bilgiler Özeti GT Biopharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? OXIA temel i̇stati̇sti̇kler Piyasa değeri €3.89m Kazançlar(TTM ) -€7.13m Gelir(TTM ) n/a
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) OXIA gelir tablosu (TTM ) Gelir US$0 Gelir Maliyeti US$0 Brüt Kâr US$0 Diğer Giderler US$7.60m Kazançlar -US$7.60m
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
